for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amgen, Inc.

AMGN.O

Latest Trade

254.21USD

Change

2.91(+1.16%)

Volume

2,513,035

Today's Range

251.78

 - 

255.73

52 Week Range

210.28

 - 

276.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
251.30
Open
251.78
Volume
2,513,035
3M AVG Volume
57.22
Today's High
255.73
Today's Low
251.78
52 Week High
276.69
52 Week Low
210.28
Shares Out (MIL)
574.55
Market Cap (MIL)
144,385.40
Forward P/E
15.43
Dividend (Yield %)
2.80

Next Event

Amgen Inc at Bank of America Global Research Healthcare Conference (Virtual)

Latest Developments

More

Amgen Says FDA Accepts Co's New Drug Application For Otezla

Amgen Says Provides Updated Information On Lumakras Dose Comparison Study

Amgen Posts Qtrly Adjusted Earnings Per Share $3.70

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry

Biotechnology & Drugs

Contact Info

1 Amgen Center Dr

THOUSAND OAKS, CA

91320-1730

United States

+1.805.4471000

http://www.amgen.com

Executive Leadership

Robert A. Bradway

Chairman of the Board, President, Chief Executive Officer

Peter H. Griffith

Chief Financial Officer, Executive Vice President

Jonathan P. Graham

Executive Vice President, General Counsel, Secretary

Lori A. Johnston

Executive Vice President - Human Resources

Murdo Gordon

Executive Vice President - Global Commercial Operations

Key Stats

2.38 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

23.7K

2019

23.7K

2020

25.4K

2021(E)

26.0K
EPS (USD)

2018

14.400

2019

14.820

2020

16.600

2021(E)

16.286
Price To Earnings (TTM)
20.81
Price To Sales (TTM)
5.74
Price To Book (MRQ)
15.49
Price To Cash Flow (TTM)
13.58
Total Debt To Equity (MRQ)
350.17
LT Debt To Equity (MRQ)
333.50
Return on Investment (TTM)
14.24
Return on Equity (TTM)
11.41

Latest News

Latest News

IN BRIEF: Amgen sues Aurobindo over proposed generic for dialysis patients

Amgen Inc sued generic drugmaker Aurobindo Pharma Ltd in Delaware federal court, alleging in a complaint entered Friday that Aurobindo's planned generic of its drug Parsabiv to treat a parathyroid condition in dialysis patients will infringe its patents.

US STOCKS-Dow, Nasdaq weighed down by Microsoft, Amgen; all eyes on Fed

* Dow down 0.35%, S&P flat, Nasdaq off 0.23% (Updates prices to early afternoon)

Amgen profit, sales fall on lower drug prices; shares drop 3.4%

U.S. biotech Amgen Inc on Tuesday said its first-quarter sales and profit fell due to a 7% drop in its net drug prices and the COVID-19 pandemic, which continued to limit patient interactions with healthcare providers.

Amgen 1st-quarter profit, sales fall; lower drug prices cited

U.S. biotech Amgen Inc on Tuesday said its first-quarter sales and profit fell due to a 7% drop in its net drug prices and the COVID-19 pandemic, which continued to limit patient interactions with healthcare providers.

Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market

Drugmaker Amgen Inc is buying Five Prime Therapeutics for about $1.9 billion to expand its line of gastric cancer drug candidates and its presence in Asia-Pacific, the companies said on Thursday.

AstraZeneca-Amgen drug could widen treatment options for severe asthma

AstraZeneca and Amgen's experimental drug reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers.

Amgen loses bid to revive patents for cholesterol drug Repatha

A federal appeals court has rejected a bid by Amgen Inc to revive patents on its cholesterol drug Repatha after they were ruled invalid by a district court, a victory for Regeneron Pharmaceuticals Inc and Sanofi SA, which sell a rival drug.

Amgen issues 2021 outlook below Street view, shares dip

U.S. biotech Amgen Inc on Tuesday provided a 2021 earnings forecast below Wall Street estimates and said it had paused or halted enrollment for clinical trials of three cancer drugs.

Amgen 4th-quarter profit rises, 2021 outlook below Street view

Amgen Inc on Tuesday reported a higher-than-expected quarterly profit as sales of newer drugs offset lower revenue from older off-patent medications, but the biotech company forecast 2021 earnings below Wall Street estimates.

Bristol Myers psoriasis drug succeeds in late-stage study

Bristol Myers Squib said on Tuesday its experimental oral drug for plaque psoriasis significantly reduced the extent and severity of the skin condition and was more effective than a placebo and Amgen Inc's Otezla.

AstraZeneca-Amgen drug fails main goal of late-stage asthma study

AstraZeneca and Amgen said on Tuesday their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients' dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.

REFILE-AstraZeneca-Amgen experimental drug fails late-stage asthma study

Drugmakers AstraZeneca and Amgen said on Tuesday their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients' dependence on steroids while keeping the condition in check in a late-stage trial.

IN BRIEF: Judge denies Coherus fees in Neulasta patent fight with Amgen

Coherus BioSciences, which last year introduced a biosimilar version of Amgen’s oncology drug Neulasta, cannot recover attorneys’ fees for defeating Amgen’s patent-infringement lawsuit, U.S. District Judge Leonard Stark held Monday in Delaware.

Amgen, AstraZeneca say experimental asthma drug meets trial goal

Drugmakers Amgen Inc and AstraZeneca Plc said on Tuesday a pivotal trial found that their experimental medication tezepelumab significantly reduced asthma attacks for people with severe forms of the respiratory condition compared to a placebo.

Bristol Myers psoriasis drug succeeds in late-stage study

Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla in a late-stage study.

Osteoporosis drug helps Amgen third-quarter profit beat estimates

Amgen Inc <AMGN.O> on Wednesday said third-quarter adjusted profit rose 17% due to stronger sales of drugs such as osteoporosis treatment Prolia and psoriasis medication Otezla, bucking challenges from lower drug prices and COVID-19.

Osteoporosis drug helps Amgen third-quarter profit beat estimates

Amgen Inc on Wednesday said its third-quarter adjusted profit rose 17% due to stronger sales of drugs including the osteoporosis treatment Prolia and recently-acquired psoriasis medication Otezla.

IN BRIEF: Federal Circuit won’t revisit Amgen’s win on blockbuster Enbrel patents

The U.S. Court of Appeals for the Federal Circuit on Tuesday declined further review of a panel decision that blocked Novartis AG’s Sandoz unit from offering a biosimilar of Amgen’s arthritis drug Enbrel (etanercept) until 2029.

Lilly, Amgen partner to manufacture potential COVID-19 drugs

Eli Lilly and Co has partnered with Amgen Inc to increase the supply of its experimental COVID-19 antibody treatments, a day after one of the drugs was shown to reduce the need for hospitalization.

Lilly partners with Amgen for manufacturing potential COVID-19 drugs

Eli Lilly and Co on Thursday entered into an agreement with Amgen Inc to increase the supply capacity of the drugmaker's experimental COVID-19 antibody treatments.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up